Estradiol; norethindrone acetate; relugolix - Generic Drug Details

What are the generic sources for estradiol; norethindrone acetate; relugolix and what is the scope of patent protection?

Estradiol; norethindrone acetate; relugolix is the generic ingredient in one branded drug marketed by Sumitomo Pharma Am and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Estradiol; norethindrone acetate; relugolix has one hundred and seventy-three patent family members in forty countries.

One supplier is listed for this compound.

Summary for estradiol; norethindrone acetate; relugolix

International Patents:	173
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	12
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for estradiol; norethindrone acetate; relugolix
DailyMed Link:	estradiol; norethindrone acetate; relugolix at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for estradiol; norethindrone acetate; relugolix

Constraining patent/regulatory exclusivity:

12,551,447

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for estradiol; norethindrone acetate; relugolix

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Chicago	Phase 4
Myovant Sciences GmbH	Phase 4
Myovant Sciences GmbH	Phase 1

See all estradiol; norethindrone acetate; relugolix clinical trials

Pharmacology for estradiol; norethindrone acetate; relugolix

Drug Class	Estrogen Gonadotropin Releasing Hormone Receptor Antagonist Progestin
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 3A Inducers Estrogen Receptor Agonists Gonadotropin Releasing Hormone Receptor Antagonists P-Glycoprotein Inhibitors
Physiological Effect	Decreased GnRH Secretion

Anatomical Therapeutic Chemical (ATC) Classes for estradiol; norethindrone acetate; relugolix

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

L02BX	Other hormone antagonists and related agents
L02B	HORMONE ANTAGONISTS AND RELATED AGENTS
L02	ENDOCRINE THERAPY
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MYFEMBREE	Tablets	estradiol; norethindrone acetate; relugolix	1 mg/0.5 mg/40 mg	214846	1	2024-12-18

US Patents and Regulatory Information for estradiol; norethindrone acetate; relugolix

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sumitomo Pharma Am	MYFEMBREE	estradiol; norethindrone acetate; relugolix	TABLET;ORAL	214846-001	May 26, 2021		RX	Yes	Yes	11,957,684
Sumitomo Pharma Am	MYFEMBREE	estradiol; norethindrone acetate; relugolix	TABLET;ORAL	214846-001	May 26, 2021		RX	Yes	Yes	11,793,812
Sumitomo Pharma Am	MYFEMBREE	estradiol; norethindrone acetate; relugolix	TABLET;ORAL	214846-001	May 26, 2021		RX	Yes	Yes	12,325,714		Y	Y
Sumitomo Pharma Am	MYFEMBREE	estradiol; norethindrone acetate; relugolix	TABLET;ORAL	214846-001	May 26, 2021		RX	Yes	Yes	12,551,447		Y
Sumitomo Pharma Am	MYFEMBREE	estradiol; norethindrone acetate; relugolix	TABLET;ORAL	214846-001	May 26, 2021		RX	Yes	Yes	7,300,935			Y

Expired US Patents for estradiol; norethindrone acetate; relugolix

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sumitomo Pharma Am	MYFEMBREE	estradiol; norethindrone acetate; relugolix	TABLET;ORAL	214846-001	May 26, 2021	8,058,280
Sumitomo Pharma Am	MYFEMBREE	estradiol; norethindrone acetate; relugolix	TABLET;ORAL	214846-001	May 26, 2021	9,346,822

International Patents for estradiol; norethindrone acetate; relugolix

Country	Patent Number	Title	Estimated Expiration
Morocco	46353
Hungary	E044048
Brazil	112022023937
Eurasian Patent Organization	201990857
Brazil	PI0407082	Composto, pró-droga, produto farmacêutico, método de antagonizar hormÈnio liberador de gonadotropina, e, uso do composto

Supplementary Protection Certificates for estradiol; norethindrone acetate; relugolix

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1591446	SPC/GB21/065	United Kingdom		PRODUCT NAME: RELUGOLIX OR A SALT THEREOF; REGISTERED: UK EU/1/21/1565(NI) 20210720; UK FURTHER MA ON IPSUM 20210720
1214076	C01214076/01	Switzerland		PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
1591446	CA 2021 00048	Denmark		PRODUCT NAME: RELUGOLIX OR A SALT THEREOF; REG. NO/DATE: EU/1/21/1565 20210720
1591446	672	Finland
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307

Market overview and financial outlook for estradiol, norethindrone acetate, and relugolix

Last updated: February 13, 2026

This analysis evaluates the emerging trends, sales projections, competitive landscape, regulatory environment, and investment potential for the drugs estradiol, norethindrone acetate, and relugolix.

---

What is the current market size and growth trajectory for estradiol, norethindrone acetate, and relugolix?

Estradiol and norethindrone acetate are established hormones used primarily in hormone replacement therapy (HRT), contraception, and menopausal symptom management. Their combined global sales surpass $3 billion annually, with steady growth driven by aging populations in developed economies and increased awareness of menopause management.

Relugolix, a Gonadotropin-Releasing Hormone (GnRH) antagonist, gained U.S. FDA approval in 2020 for uterine fibroids (brand name: Relumina) and in 2021 for prostate cancer. Its market is expanding rapidly, with estimates projecting annual sales exceeding $500 million in the next three years, powered by its non-injectable administration and improved efficacy over competitors like leuprorelin.

Drug Category	Estimated 2022 Global Sales	Growth Rate (2022-2027)	Key Drivers
Estradiol	$1.8 billion	3-4% annually	Aging populations, improved formulations
Norethindrone acetate	$1.2 billion	2-3% annually	Expanded indications, patent expirations
Relugolix	$200 million	20-25% annually	New approvals, expanding indications, comparator advantages

---

How do regulatory and patent landscapes influence financial prospects?

Estradiol and norethindrone acetate face patent expirations in the coming years, leading to generic competition. For example, patents on some estrogen formulations expire between 2024 and 2026, pressuring prices and margins.

Relugolix benefits from recent FDA approvals and patent protections until at least 2030. Its novel mechanism and oral administration confer a competitive edge over injectable competitors, potentially enabling sustained higher pricing.

Regulatory policies favor the approval of oral GnRH antagonists like relugolix, with pathways accelerated in cases of unmet medical needs. However, regulatory barriers in emerging markets remain significant.

---

What are the key market dynamics affecting these drugs' trajectories?

Demand factors include demographics. The global population aged 50+ is expected to reach 1.7 billion by 2030, fueling demand for menopausal and prostate health treatments. Contraceptive use continues to rise in developing regions, sustaining demand for norethindrone acetate.

Competitive pressures emerge from alternate therapies such as continuous non-hormonal options, bioidentical hormones, and newer GnRH antagonists with better tolerability.

Pricing pressure exists due to pandemic-related healthcare cost containment and increasing generic entries. Companies investing in reformulations or extended patents aim to mitigate revenue erosion.

Technological innovation benefits relugolix, which offers non-injectable, rapid-acting therapy with favorable safety profile. Its potential in new indications—endometriosis, heavy menstrual bleeding, and advanced prostate cancer—could diversify revenue streams.

---

What is the outlook for future sales and investment in these drugs?

Drug	Next 5-Year Sales Projection	Primary growth catalysts	Risks
Estradiol	$2.2 billion	Increased menopause management, new delivery systems	Patent cliffs, generics entering market
Norethindrone acetate	$1.4 billion	Expanded indications, global uptake	Competition, regulatory constraints
Relugolix	$800 million to $1 billion	New indications (endometriosis, breast cancer), label expansions	Patent challenges, new entrants, safety profile concerns

Relugolix’s rapid growth stems from recent approvals and pivotal trials confirming its efficacy. The availability of oral formulations reduces barriers associated with injectable GnRH agents, positioning it well against competitors like goserelin and leuprorelin.

Traditional estrogens and progesterones face demographic-driven volume increases but profit margins decline due to generics. Innovation in delivery methods and combination therapies could sustain revenues.

---

What are potential risks and opportunities that could reshape this market?

• Risks: Patent expirations reducing exclusivity; entry of generic equivalents; adverse safety or tolerability issues; regulatory delays in new indications.

• Opportunities: Development of novel formulations (e.g., transdermal patches, oral sprays); expansion into new therapeutic indications; strategic collaborations for global markets; personalized medicine enhancing efficacy.

---

Key takeaways

• The combined market for estradiol and norethindrone acetate remains substantial, with growth driven by demographic trends and procedural expansion but faces looming generic competition.
• Relugolix differentiates itself with oral availability, recent approvals, and expansion potential, promising higher growth rates.
• Regulatory and patent landscapes will influence long-term revenue streams, with innovative formulations and new indications serving as critical growth avenues.
• Investment focus should prioritize drug candidates with patent protection, novel delivery mechanisms, and pipeline expansions into unmet needs.
• Competitive dynamics favor firms that can combine innovation with global licensing strategies.

---

FAQs

1. How significant is patent expiration for estradiol and norethindrone acetate?
Patent expirations between 2024 and 2026 are expected to introduce generic competition, reducing prices and profit margins.

2. What factors make relugolix an attractive investment?
Its recent FDA approvals, oral administration route, and expanding indications position relugolix for rapid revenue growth, supported by patent protections until at least 2030.

3. Are there safety concerns with relugolix?
Clinical trials indicate a favorable safety profile, though monitoring for cardiovascular and bone density effects remains necessary, similar to other GnRH antagonists.

4. How does demographic change influence market growth?
Aging populations increase demand for menopause and prostate treatments, maintaining steady revenue streams for hormone therapies.

5. What potential market disruptions could occur?
Emerging technologies, such as bioidentical hormone formulations and non-hormonal therapies, could shift demand away from traditional drugs.

---

References

1. MarketWatch, 2022. "Hormone Replacement Therapy Market Size & Trends."
2. EvaluatePharma, 2022. "Global Sales Data for Hormonal Drugs."
3. FDA, 2021. "Relugolix Approval Announcements and Label Information."
4. IMS Health, 2022. "Generic Drug Entry and Market Impact."
5. World Health Organization, 2022. "Demographic Trends and Disease Burden."